🩺

Gastroenterology

58 drugs in pipeline from 10 companies

Drugs in Pipeline

Companies

Upcoming Catalysts

Phase 3 Trials

Upcoming Catalysts

days

KYTXPhase 2$65M

Standard lymphodepletion regimen Phase 2 Results Expected

Standard lymphodepletion regimen• Lupus Nephritis25

Apr 15Estimated

CT.gov

00%

days

NTLAPhase 3$1.9B

NTLA-2002 Phase 3 Results Expected

NTLA-2002• Hereditary Angioedema60

Apr 15Estimated

CT.gov

00%

days

GILDPhase 2$60.0B

Tilpisertib Fosmecarbil Phase 2 Results Expected

Tilpisertib Fosmecarbil• Ulcerative Colitis176

Apr 15Estimated

CT.gov

00%

days

ODYYPhase 2$2M

OD-07656 Phase 2 Results Expected

OD-07656• Ulcerative Colitis (UC)57

Apr 15Estimated

CT.gov

00%

days

GILDPhase 2$60.0B

Placebo Phase 2 Results Expected

Seladelpar 10 mg• Primary Biliary Cholangitis176

Apr 15Estimated

CT.gov

00%

days

ABVXPhase 3$10.3B

ABX464 Phase 3 Results Expected

ABX464• Ulcerative Colitis1,116

Apr 15Estimated

CT.gov

00%

LSTAPhase 2$24M

certepetide Phase 2 Results Expected

certepetide• Cholangiocarcinoma67

Apr 18Estimated

CT.gov

00%

ANROPhase 2$590M

DR30206 Phase 2 Results Expected

DR30206• Gastrointestinal Cancer186

Apr 30Estimated

CT.gov

00%

View all catalysts

Pipeline by Phase

Phase 3

Active Companies

CELG-RI

BRISTOL MYERS SQUIBB CO

Novartis AG

Amgen Inc.

Gilead Sciences, Inc.

AstraZeneca PLC

ASTRAZENECA PLC

TAKEDA PHARMACEUTICAL CO LTD

2 drugs

TAK

TAKEDA PHARMACEUTICAL CO LTD

1 drugs

LLY

Eli Lilly and Company

2 drugs

ABT

ABBOTT LABORATORIES

4 drugs

Related Conditions

gastrointestinalgiliverhepaticcirrhosiscrohnulcerative colitisibsgerdpancreatitisceliacconstipationdiarrhea